Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Public ClinicalTrials.gov record NCT02392676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Whose Tumours Carry Loss of Function Somatic BRCA Mutation(s) or Loss of Function Mutation(s) in Tumour Homologous Recombination Repair -Associated Genes
Study identification
- NCT ID
- NCT02392676
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- OLAPARIB Drug
- PLACEBO Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 96 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2016
- Primary completion
- May 31, 2019
- Completion
- May 31, 2019
- Last update posted
- May 1, 2016
2016 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Mobile | Alabama | — | — |
| Research Site | Phoenix | Arizona | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Stanford | California | — | — |
| Research Site | Augusta | Georgia | — | — |
| Research Site | Park Ridge | Illinois | — | — |
| Research Site | Iowa City | Iowa | — | — |
| Research Site | Louisville | Kentucky | — | — |
| Research Site | Covington | Louisiana | — | — |
| Research Site | Scarborough | Maine | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Albany | New York | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
| Research Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02392676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02392676 live on ClinicalTrials.gov.